141080 — LigaChem Biosciences Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeLarge CapNeutral

Annual cashflow statement for LigaChem Biosciences, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-23,391	-45,092	-73,704	7,800	-91,552
Depreciation
Amortisation
Deferred Taxes
Non-Cash Items	3,058	13,365	5,443	-14,194	-13,147
Unusual Items
Purchased R&D
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-24,765	20,475	1,353	79,862	-26,443
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-42,049	-7,136	-62,236	78,476	-124,533
Capital Expenditures	-18,603	-4,772	-2,202	-5,701	-6,041
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-25,341	-11,397	11,569	-451,673	100,182
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	-43,944	-16,169	9,367	-457,374	94,141
Financing Cash Flow Items	-26.3	-2.64	-4.21	-61.6	0
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	171,292	3,199	-1,909	443,379	-629
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	85,291	-21,975	-54,911	65,858	-30,262